ABBV vs KRYS
As of Sep 20, 2026, AbbVie (ABBV) scores 7.8/10 and Krystal Biotech (KRYS) 5.5/10 on AlphaStocks' five-model composite, so ABBV scores higher. ABBV trades 102% above its model fair value; KRYS trades 54% above its model fair value.
ABBV
AbbVie Inc.
7.8
Strong Buy
$263.86
KRYS
Krystal Biotech, Inc.
5.5
Consider Buy
$336.82
ABBV vs KRYS: Which is the Better Investment?
AbbVie Inc. (ABBV) scores 7.8/10 while Krystal Biotech, Inc. (KRYS) scores 5.5/10 on AlphaStocks' composite model. AbbVie Inc. has the higher composite rating of Strong Buy. On a P/E basis, Krystal Biotech, Inc. trades at 49.3x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | ABBV | KRYS |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 7.8/10▲ | 5.5/10 |
| Rating | Strong Buy▲ | Consider Buy |
| Price | $263.86 | $336.82 |
| P/E Ratio | 110.7 | 49.3▲ |
| ROE | -143.0% | 17.2%▲ |
| Market Cap | $468B | $10B |
| Fair Value | $130.53 | $218.10 |
| Dividend Yield | 2.7% | — |
| Sector Rank | #2 of 168▲ | #75 of 168 |
| Model Verdicts | ||
| Piotroski | Strong▲ | Attractive |
| Buffett | Strong▲ | Neutral |
| Graham | Neutral▲ | Caution |
| Lynch | Neutral▲ | Limited Data |
| Greenblatt | Neutral▲ | Limited Data |
Related comparisons
ABBV vs KRYS: Which Stock Scores Higher?
AbbVie Inc. (ABBV) and Krystal Biotech, Inc. (KRYS) are both in the Health Care sector. ABBV currently leads with a composite score of 7.8/10 (Strong Buy) compared to KRYS's 5.5/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer